{"DataElement":{"publicId":"7717116","version":"1","preferredName":"Neoplasm Destruction Method Other Specify Text","preferredDefinition":"The free text field that describes other neoplasm destruction methods.","longName":"other_helps","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"7717115","version":"1","preferredName":"Neoplasm Destruction Method","preferredDefinition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._The act of destroying; demolition or annihilation._A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.","longName":"7717113v1.0:2730351v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"7717113","version":"1","preferredName":"Neoplasm Destruction","preferredDefinition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.:The act of destroying; demolition or annihilation.","longName":"C3262:C62100","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Destruction","conceptCode":"C62100","definition":"The act of destroying; demolition or annihilation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6753E0C-212F-3A1A-E053-4EBD850A7FDE","latestVersionIndicator":"Yes","beginDate":"2021-07-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-07-06","modifiedBy":"ONEDATA","dateModified":"2021-07-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2730351","version":"1","preferredName":"Method","preferredDefinition":"A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.","longName":"C71460","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Method","conceptCode":"C71460","definition":"A means, manner of procedure, or systematic course of actions that have to be performed in order to accomplish a particular goal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4692C84F-EB01-324C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-02-20","modifiedBy":"ONEDATA","dateModified":"2008-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435033","version":"1","preferredName":"Techniques","preferredDefinition":"A practiced and regimented skill or series of actions.","longName":"C16847","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87DA-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCG:Center for Cancer Genomics","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6753E0C-213D-3A1A-E053-4EBD850A7FDE","latestVersionIndicator":"Yes","beginDate":"2021-07-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-07-06","modifiedBy":"KUMMEROA","dateModified":"2021-07-21","changeDescription":"2021-7-6 ak Created for CCG HOPE-CARE.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2857322","version":"1","preferredName":"Other Specify Text","preferredDefinition":"The free text field that describes another response when other is chosen from a list of values.","longName":"OTHR_SPEC_TXT","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2857047","version":"1","preferredName":"Other Specify Text","preferredDefinition":"Not otherwise specified.:Specify; be specific about something; define clearly.:Text; the words of something written.","longName":"C17649:C25685:C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"660AABE0-46ED-4890-E040-BB89AD431D5B","latestVersionIndicator":"Yes","beginDate":"2009-03-26","endDate":null,"createdBy":"SCOTTLO","dateCreated":"2009-03-26","modifiedBy":"ONEDATA","dateModified":"2009-03-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"6648A78E-AB33-047A-E040-BB89AD4324AB","latestVersionIndicator":"Yes","beginDate":"2009-03-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-03-29","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"8/22/17 tt transferred context, added registration status and CSI per Round 5 finalization task. Modified for The Cancer Genome Atlas (TCGA) by request of T. Lichtenberg (JP) 12/2010.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6705584","version":"1","longName":"CCG PTCL (Center for Cancer Genomics - Peripheral T Cell Lymphoma)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"7715738","version":"1","longName":"HOPE-CARE","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Which other methods were used","type":"Preferred Question Text","description":"Which other methods were used to support tumor destruction? (please specify)","url":null,"context":"NCIP"}],"origin":"CCG:Center for Cancer Genomics","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C67473CB-7A2C-6872-E053-4EBD850AE771","latestVersionIndicator":"Yes","beginDate":"2021-07-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-07-06","modifiedBy":"KUMMEROA","dateModified":"2021-07-21","changeDescription":"202-7-6 ak Created for CCG HOPE-CARE.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}